Literature DB >> 19491915

Systemic lupus erythematosus clinical trials-an interim analysis.

Maria Dall'Era1, David Wofsy.   

Abstract

Since the current standards for drug approval were established nearly half a century ago, no drug has been approved for the treatment of systemic lupus erythematosus (SLE). Despite this sobering history, interest in drug development for SLE has heightened in the past few years. This enthusiasm has been fueled in large part by the success of biologic therapy for rheumatoid arthritis and other autoimmune diseases. Unfortunately, despite considerable clinical trial activity, this interest has not yet translated into the discovery of an effective treatment for SLE. This article provides an analysis of the major clinical trials in SLE, and offers an interpretation of the results that could illuminate the path forward.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19491915     DOI: 10.1038/nrrheum.2009.79

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  13 in total

1.  Sequential therapies for proliferative lupus nephritis.

Authors:  Gabriel Contreras; Victoriano Pardo; Baudouin Leclercq; Oliver Lenz; Elaine Tozman; Patricia O'Nan; David Roth
Journal:  N Engl J Med       Date:  2004-03-04       Impact factor: 91.245

2.  Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.

Authors:  K G C Smith; R B Jones; S M Burns; D R W Jayne
Journal:  Arthritis Rheum       Date:  2006-09

3.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

Authors:  Ellen M Ginzler; Mary Anne Dooley; Cynthia Aranow; Mimi Y Kim; Jill Buyon; Joan T Merrill; Michelle Petri; Gary S Gilkeson; Daniel J Wallace; Michael H Weisman; Gerald B Appel
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

4.  Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis.

Authors:  G G Illei; H A Austin; M Crane; L Collins; M F Gourley; C H Yarboro; E M Vaughan; T Kuroiwa; C L Danning; A D Steinberg; J H Klippel; J E Balow; D T Boumpas
Journal:  Ann Intern Med       Date:  2001-08-21       Impact factor: 25.391

5.  Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group.

Authors:  T M Chan; F K Li; C S Tang; R W Wong; G X Fang; Y L Ji; C S Lau; A K Wong; M K Tong; K W Chan; K N Lai
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

6.  Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial.

Authors:  Michelle A Petri; Robert G Lahita; Ronald F Van Vollenhoven; Joan T Merrill; Michael Schiff; Ellen M Ginzler; Vibeke Strand; Arlene Kunz; Kenneth J Gorelick; Kenneth E Schwartz
Journal:  Arthritis Rheum       Date:  2002-07

7.  Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.

Authors:  Michelle A Petri; Philip J Mease; Joan T Merrill; Robert G Lahita; Mark J Iannini; David E Yocum; Ellen M Ginzler; Robert S Katz; Oscar S Gluck; Mark C Genovese; Ronald Van Vollenhoven; Kenneth C Kalunian; Susan Manzi; Maria W Greenwald; Jill P Buyon; Nancy J Olsen; Michael H Schiff; Arthur F Kavanaugh; Jacques R Caldwell; Rosalind Ramsey-Goldman; E William St Clair; Allan L Goldman; Rita M Egan; Richard P Polisson; Kevin G Moder; Naomi F Rothfield; Robert T Spencer; Kathryn Hobbs; Barri J Fessler; Leonard H Calabrese; Larry W Moreland; Stanley B Cohen; Betty J Quarles; Vibeke Strand; Marc Gurwith; Kenneth E Schwartz
Journal:  Arthritis Rheum       Date:  2004-09

8.  Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition.

Authors:  Lena Schiffer; Jayashree Sinha; Xiaobo Wang; Weiqing Huang; Gero von Gersdorff; Mario Schiffer; Michael P Madaio; Anne Davidson; Gero Von Gonsdorff
Journal:  J Immunol       Date:  2003-07-01       Impact factor: 5.422

9.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

10.  B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response.

Authors:  Kristine P Ng; Geraldine Cambridge; Maria J Leandro; Jonathan C W Edwards; Michael Ehrenstein; David A Isenberg
Journal:  Ann Rheum Dis       Date:  2007-04-05       Impact factor: 19.103

View more
  4 in total

Review 1.  B cells as therapeutic targets in SLE.

Authors:  Iñaki Sanz; F Eun-Hyung Lee
Journal:  Nat Rev Rheumatol       Date:  2010-06       Impact factor: 20.543

Review 2.  Novel therapeutic approaches to lupus glomerulonephritis: translating animal models to clinical practice.

Authors:  Harini Bagavant; Kambiz Kalantarinia; Yogesh Scindia; Umesh Deshmukh
Journal:  Am J Kidney Dis       Date:  2011-01-15       Impact factor: 8.860

Review 3.  Systemic lupus erythematosus: a therapeutic challenge for the XXI century.

Authors:  Manuel F Ugarte-Gil; Graciela S Alarcón
Journal:  Clin Rheumatol       Date:  2014-02-28       Impact factor: 2.980

Review 4.  Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLE.

Authors:  Ding-Lei Su; Zhi-Min Lu; Min-Ning Shen; Xia Li; Ling-Yun Sun
Journal:  J Biomed Biotechnol       Date:  2012-02-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.